



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/010,860	12/07/2001	Marc S. Collett	1282	8207
110	7590	07/30/2002		
DANN DORFMAN HERRELL & SKILLMAN SUITE 720 1601 MARKET STREET PHILADELPHIA, PA 19103-2307			EXAMINER	
			HORLICK, KENNETH R	
		ART UNIT	PAPER NUMBER	
		1637	J	
DATE MAILED: 07/30/2002				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/010,860	COLLETT ET AL.
Examiner	Art Unit	
HORLICK	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 December 2001.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-22 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) 15-22 is/are allowed.

6) Claim(s) 1-14 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
4) Interview Summary (PTO-413) Paper No(s) _____.
5) Notice of Informal Patent Application (PTO-152)
6) Other:

Sharon Thornton
SHARON N. THORNTON
PATENT ANALYST

Art Unit: 1637

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Houghton et al. (US 5,371,017) in view of Suzich et al. (1993).

These claims are drawn to recombinantly-produced native, authentic, enzymatically active NTPase/RNA helicase of hepatitis C virus (HCV), said enzyme comprising amino acids 1027-1657 of the HCV NS3 gene product; and to a recombinant method of producing said enzyme.

Houghton et al. disclose recombinant expression of the HCV NS3 gene product, including the entire coding region, fusion proteins, and truncated and altered versions of said gene product (see column 2, lines 5-9). In lines 18-55 of column 4, a "DNA construct encoding the entire NS3 domain" is specifically taught. Columns 7-10 disclose various well-established recombinant expression means in the art, including both expression of fusion proteins and nonfused (native) proteins (see especially column 10, lines 6-16). While specific examples of fusion proteins are disclosed in this patent, the teachings as a whole clearly cover recombinant expression of the full length, native NS3 gene product.

Houghton et al. do not specifically disclose an HCV NS3 gene product comprising amino acids 1027-1657.

Suzich et al. teach that the entire HCV NS3 gene product was known to reside in amino acids 1027-1657 of the HCV polyprotein (see Fig. 1A on page 6153).

One of ordinary skill in the art would have been motivated to apply the teachings of full-length, native recombinant expression of HCV NS3 (Houghton et al.) to an enzyme comprising amino acids 1027-1657 because Suzich et al. taught that these amino acids defined the HCV NS3 gene product. It would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to produce and use the claimed HCV NS3 proteins.

Art Unit: 1637

2. The arguments of the response filed 04/20/01 have been fully considered, but are not found persuasive. With respect to the Houghton et al. patent, no new arguments have been provided; the position of the Office is already of record. With respect to the Suzich et al. reference, the Office has relied only on the teaching that the entire HCV NS3 gene product was known to reside in amino acids 1027-1657 of the HCV polyprotein; the other teachings necessary to support the rejection are found in the Houghton et al. patent.

3. Claims 15-22 are allowable.

4. Houghton et al. (US 6,194,140) is made of record as a reference of interest.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth R Horlick whose telephone number is 703-308-3905. The examiner can normally be reached on Monday-Thursday 6:30AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Kenneth R Horlick
Primary Examiner
Art Unit 1637

July 17, 2002

Kenneth R. Horlick, Ph.D.